Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1099-1105

  Mühlbauer, Marcus ^a   Langenbach, Nicole ^a   Stolz, Wilhelm ^a   Hein, Ruediger ^b   Landthaler, M ^a   Buettner, Reinhard ^a   Bosserhoff, Anja Katrin ^a,c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RNA;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0345086406     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Curry, B. J., Myers, K., and Hersey, P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J. Clin. Oncol., 16: 1760-1769, 1998.
2. Reintgen, D. S., and Conrad, A. J. Detection of occult melanoma cells in sentinel lymph nodes and blood. Semin. Oncol., 24 (Suppl.): S11-S15, 1997.
3. Mellado, B., Colomer, D., Castel, T., Munoz, M., Carballo, E., Galan, M., Mascaro, J. M., Vives-Corrons, J. L., Grau, J. J., and Estape, J. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J. Clin. Oncol., 14: 2091-2097, 1996.
4. Blesch, A., Bosserhoff, A. K., Apfel, R., Behl, C., Hessdörfer, B., Schmitt, A., Jachimczak, P., Lottspeich, F., Schlingensiepen, H., Buettner, R., and Bogdahn, U. Cloning of a novel malignant melanomaderived growth regulatory protein, MIA. Cancer Res., 54: 5695-5701, 1994.
5. Bosserhoff, A. K., Hein, R., Bogdahn, U., and Buettner, R. Structure and promoter analysis of the gene encoding the human melanomainhibiting-protein, MIA. J. Biol. Chem., 271: 490-495, 1996.
6. van Groningen, J. J. M., Bloemers, H. P., and Swart, G. W. Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res.. 55: 6237-6243, 1995.
7. Bosserhoff, A. K., Moser, M., Hein, R., Landthaler, M., and Buettner, R. In situ expression patterns of melanoma-inhibiting activity (MIA) in malignant melanomas and breast cancers. J. Pathol., 187: in press, 1999.
8. Bosserhoff, A-K., Kaufmann, M., Kaluza, B., Bartke, I., Zirngibl, H., Hein, R., Stolz, W., and Buettner, R. Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma. Cancer Res., 57: 3149-3153, 1997.
9. Dietz, U., and Sandell, L. J. Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J. Biol. Chem., 271: 3311-3316, 1996.
10. Bosserhoff, A. K., Kondo, S., Moser, M., Dietz, U., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Buettner, R., and Sandell, L. J. The mouse MIA/CDneg. RAP gene: structure, chromosomal localization and expression in cartilage and chondrosarcoma. Dev. Dyn., 208: 516-525, 1997.
11. Abu-hadid, M., and Perez, R. Detection of mRNA for potential diagnostic marker genes in melanoma and non-melanoma tumor specimens by RT-PCR. Proc. Am. Assoc. Cancer Res., 37: 199, 1996.
12. Smith, B., Selby, P., Southgate, J., Pittman, K., Bradley, C., and Blair, G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet, 338: 1227-1229, 1991.
13. Sarantou, T., Chi, D. D., Garrison, D. A., Conrad, A. J., Schmid, P., Morton, D. L., and Hoon, D. S. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res., 57: 1371-1376, 1997.
14. Kunter, U., Buer, J., Probst, M., Duensing, S., Dalimann, I., Grosse, J., Kirchner, H., Schluepen, E. M., Volkenandt, M., Ganser, A., and Atzpodien, J. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J. Natl. Cancer Inst., 88: 590-594, 1996.
15. Brossart, P., Schmier, J. W., Kruger, S., Willhauck, M., Scheibenbogen, C., Mohler, T., and Keilholz, U. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res., 55: 4065-4068, 1995.
16. Hanekom, G. S., Johnson, C. A., and Kidson, S. H. An improved and combined reverse transcription-polymerase chain reaction assay for reliable detection of metastatic melanoma cells in peripheral blood. Melanoma Res., 7: 111-116, 1997.
17. Glaser, R., Rass, K., Seiter, S., Hauschild, A., Christophers, E., and Tilgen, W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J. Clin. Oncol., 15: 2818-2825, 1997.
18. Reinhold, U., Ludtke-Handjery, H. C., Schnautz, S., Kreysel, H. W., and Abken, H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J. Invest. Dermatol., 108: 166-169, 1997.
19. Pittman, K., Burchill, S., Smith, B., Southgate, J., Joffe, J., Gore, M., and Selby, P. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann. Oncol., 7: 297-301, 1996.
20. Foss, A. J., Guille, M. J., Occleston, N. L., Hykin, P. G., Hungerford, J. L., and Lightman, S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br. J. Cancer., 72: 155-159, 1995.
21. Jacob, K., Bosserhoff, A. K., Wach, F., Knuechel, R., Klein, E. C., Hein, R., and Buettner, R. Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. Int. J. Cancer, 60: 668-675, 1995.
22. Breslow, A. Measurements of tumor thickness. Hum. Pathol., 9: 238-239, 1978.
23. American Joint Committee on Cancer. Manual for Staging of Cancer, Ed. 3, pp. 143-148. Philadelphia: J. B. Lippincott, 1988.
24. Fotino, M., Merson, E. J., and Allen, F. H. Micromethod for rapid separation of lymphocytes from peripheral blood. Ann. Clin. Lab. Sci., 1: 131-133, 1971.
25. Farthmann, B., Eberle, J., Krasagakis, K., Gstottner, M., Wang, N., Bisson, S., and Orfanos, C. E. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J. Invest. Dermatol., 110: 263-267, 1998.
26. Jung, F. A., Buzaid, A. C., Ross, M. I., Woods, K. V., Lee, J. J., Albitar, M., and Grimm, E. A. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J. Clin. Oncol., 15: 2826-2831, 1997.
27. Keilholz, U., Willkaick, M., Rimoldi, D., Brasseur, F., Dummer, W., Rass, K., deVries, T., Blaheta, J., Voit, C., Lethe, B., and Burchill, S. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC melanoma cooperative group. Eur. J. Cancer, 34: 750-753, 1998.
28. Ghossein, R. A., Coit, D., Brennan, M., Zhang, Z. F., Wang, Y., Bhattacharya, S., Houghton, A., and Rosai, J. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res., 4: 419-428, 1998.
29. Hofbauer, G. F., Kamarashev, J., Geertsen, R., Boni, R., Dummer, R. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J. Cutaneous Pathol., 25: 204-209, 1998.
30. Jager, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jager, D., Oesch, F., and Knuth, A. Immunoselection in vivo: independent loss of MHC class I and inelanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer., 71: 142-147, 1997.
31. Hansen, E., Wolff, N., Knuechel, R., Ruschoff, J., Hofstaedter, F., and Taeger, K. Tumor cells in blood shed from the surgical field. Arch. Surg., 130: 387-393, 1995.
32. Brossart, P., Keilholz, U., Scheibenbogen, C., Mohler, T., Willhauck, M., and Hunstein, W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J. Immunother., 15: 38-41, 1994.
33. Szenajch, J., Kozak, A., Kruszewski, A. A., Babiej, E., Chomicka, M., Struzyna, J., and Wiktorjedrzejczak, W. The effect of chemo-and chemoimmunotherapy on the presence of circulating melanoma cells in the peripheral blood: preliminary results. Acta Biochim. Pol., 45: 95-102, 1998.